[Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome].
In our work we evaluated according to Kupperman Index the effectiveness of treating menopausal signs and symptoms during the therapy with estrogen--progestagen preparation Klimonorm firm Jenapharm. During 6 months observation increase in blood pressure was not observed, neither an increase in body weight in a group of 116 women was not observed. Among these, mean Kupperman index was decreased from 28.38 to 11.6 after 3 months and up to 5.47 after 6 months therapy with Klimonorm. These patients estimated this agent as very good and good in 93.21% tolerated as very good and good in 91.43% and 91.59% of these patients planned to continue treatment with Klimonorm.
Czekanowski
R
R
Szpitala Ginekologiczno-Połozniczego, Warszawie.
Stelmachow
J
J
Radowicki
S
S
Cekański
A
A
Florczak
M
M
Chlabicz
P
P
D002979:Climacteric / Q000187:drug effects*; D003008:Cloprostenol / Q000494:pharmacology*; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000494:pharmacology*; D008875:Middle Aged; D017060:Patient Satisfaction
D004338:Drug Combinations; C097275:klimonorm; D003008:Cloprostenol; D004958:Estradiol; D016912:Levonorgestrel
Wieloośrodkowa ocena preparatu Klimonorm(R) firmy Jenapharm w leczeniuzespołu klimakterycznego.